These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29771783)

  • 1. HIV-1 Drug Resistance Among Ugandan Adults Attending an Urban Out-Patient Clinic.
    von Braun A; Sekaggya-Wiltshire C; Bachmann N; Ssemwanga D; Scherrer AU; Nanyonjo M; Kapaata A; Kaleebu P; Günthard HF; Castelnuovo B; Fehr J; Kambugu A
    J Acquir Immune Defic Syndr; 2018 Aug; 78(5):566-573. PubMed ID: 29771783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological Outcome of Patients With HIV Drug Resistance Attending an Urban Outpatient Clinic in Uganda: A Need for Structured Adherence Counseling and Third-Line Treatment Options.
    Baumann A; Musaazi J; Kambugu A; Kälin M; Weissberg D; Ssemwanga D; Fehr J; Castelnuovo B; Sekaggya-Wiltshire C; von Braun A
    J Acquir Immune Defic Syndr; 2019 Apr; 80(4):481-487. PubMed ID: 30633041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.
    Hamers RL; Wallis CL; Kityo C; Siwale M; Mandaliya K; Conradie F; Botes ME; Wellington M; Osibogun A; Sigaloff KC; Nankya I; Schuurman R; Wit FW; Stevens WS; van Vugt M; de Wit TF;
    Lancet Infect Dis; 2011 Oct; 11(10):750-9. PubMed ID: 21802367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
    Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
    Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda.
    Ndahimana Jd; Riedel DJ; Mwumvaneza M; Sebuhoro D; Uwimbabazi JC; Kubwimana M; Mugabo J; Mulindabigwi A; Kirk C; Kanters S; Forrest JI; Jagodzinski LL; Peel SA; Ribakare M; Redfield RR; Nsanzimana S
    Trop Med Int Health; 2016 Jul; 21(7):928-35. PubMed ID: 27125473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained virological response and drug resistance among female sex workers living with HIV on antiretroviral therapy in Kampala, Uganda: a cross-sectional study.
    Namale G; Kamacooko O; Bagiire D; Mayanja Y; Abaasa A; Kilembe W; Price M; Ssemwanga D; Lunkuse S; Nanyonjo M; Ssenyonga W; Mayaud P; Newton R; Kaleebu P; Seeley J
    Sex Transm Infect; 2019 Sep; 95(6):405-411. PubMed ID: 31266818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.
    Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Kityo C; Steegen K; Naniche D; Clotet B; Rinke de Wit TF; Paredes R;
    Lancet HIV; 2018 Nov; 5(11):e638-e646. PubMed ID: 30282603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland.
    Bachmann N; von Braun A; Labhardt ND; Kadelka C; Günthard HF; Sekaggya-Wiltshire C; Castelnuovo B; Kambugu A; Lejone TI; Böni J; Yerly S; Perreau M; Klimkait T; Kouyos RD; Fehr J;
    J Antimicrob Chemother; 2019 Feb; 74(2):468-472. PubMed ID: 30476115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line antiretroviral therapy failure and characterization of HIV-1 drug resistance patterns in children in Mali.
    Sylla M; Dolo O; Maiga AI; Traore FT; Coulibaly YA; Togo J; Fofana DB; Dicko-Traore F; Doumbia S; Orsega S; Diallo S; Murphy RL; Calvez V; Marcelin AG
    Arch Pediatr; 2019 Jul; 26(5):254-258. PubMed ID: 31307909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
    Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
    Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis.
    von Braun A; Sekaggya-Wiltshire C; Scherrer AU; Magambo B; Kambugu A; Fehr J; Castelnuovo B
    AIDS Res Ther; 2017 Jan; 14(1):1. PubMed ID: 28086929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
    Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
    Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
    Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone.
    Yendewa GA; Sahr F; Lakoh S; Ruiz M; Patiño L; Tabernilla A; Deen GF; Sesay M; Salata RA; Poveda E
    J Antimicrob Chemother; 2019 Jul; 74(7):2024-2029. PubMed ID: 30989237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa.
    Sigaloff KC; Hamers RL; Wallis CL; Kityo C; Siwale M; Ive P; Botes ME; Mandaliya K; Wellington M; Osibogun A; Stevens WS; van Vugt M; de Wit TF;
    J Acquir Immune Defic Syndr; 2011 Sep; 58(1):23-31. PubMed ID: 21694603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa.
    Hunt GM; Dokubo EK; Takuva S; de Oliveira T; Ledwaba J; Dube N; Moodley P; Sabatier J; Deyde V; Morris L; Raizes E
    J Antimicrob Chemother; 2017 Nov; 72(11):3141-3148. PubMed ID: 28981637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of drug-resistance using genotypic and docking analysis among anti-retroviral therapy naïve and first-line treatment failures in Salem, Tamil Nadu, India.
    Dharmalingam T; Udhaya V; Umaarasu T; Elangovan V; Rajesh SV; Shanmugam G
    Curr HIV Res; 2015; 13(2):160-72. PubMed ID: 25892414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children.
    Kityo C; Boerma RS; Sigaloff KCE; Kaudha E; Calis JCJ; Musiime V; Balinda S; Nakanjako R; Boender TS; Mugyenyi PN; Rinke de Wit TF
    J Antimicrob Chemother; 2017 Sep; 72(9):2587-2595. PubMed ID: 28673027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.